Back to Search

Defibrotide for Severe COVID-19 Treatment

Defibrotide for the Treatment of Severe COVID-19

Recruiting Phase 2 Interventional Study
Covid19
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
42 (estimated)
Sponsor
Brigham and Women's Hospital · Other
Who this trial is looking for

This trial is looking for adults with severe COVID-19 who have pneumonia. Participants will receive defibrotide to see if it's safe and helpful for this condition.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am at least 18 years old.
  • I have a confirmed active COVID-19 infection.
  • I have lung issues shown on my imaging tests.
  • I can expect to live for at least 24 more hours.
  • I have a score of 4-7 on the WHO scale.
  • I can provide consent or have someone who can.
  • I may be taking certain anticoagulants.

You may not be able to join if

  • I have significant bleeding.
  • I am receiving thrombolytic therapy.
  • I am unstable and need more than one vasopressor.
  • I am allergic to defibrotide.
  • I am pregnant or breastfeeding.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years. 2. Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR. 3. Radiographic evidence of bilateral pulmonary infiltrates. 4. A life expectancy of at least 24 hours. 5. Score of 4-7 on the WHO ordinal scale. 6. Prophylactic dose anticoagulation is allowed …
Contacts

No contact information available.

NCT ID: NCT04652115 Source: ClinicalTrials.gov